Trials / Terminated
TerminatedNCT01158417
Resveratrol in Type2 Diabetes and Obesity
Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- University at Buffalo · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.
Detailed description
The main objective of this study is to investigate the effect of resveratrol on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo. This research will investigate the hypothesis that resveratrol, when given orally to obese and type 2 diabetic subjects induces a decrease in reactive oxygen species (ROS) generation and the pro-inflammatory transcription factor nuclear factor-kB (NF-kB) and the inflammatory mediators regulated by it. The hypothesis that resveratrol suppresses the high fat, high carbohydrate (HFHC) meal induced inflammatory and oxidative response, will also be investigated. This research will also investigate the hypothesis that resveratrol intake for 12 weeks improves insulin sensitivity by lowering the Homeostasis model assessment of insulin resistance (HOMA-IR), an index of insulin resistance and, that resveratrol intake will cause an increase in incretins.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | oral |
| DRUG | Resveratrol 40 mg oral three times a day | Drug |
| DRUG | Resveratrol 500 mg oral once daily. | Resveratrol 500 mg oral once daily. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2012-07-08
- Completion
- 2012-07-08
- First posted
- 2010-07-08
- Last updated
- 2022-11-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01158417. Inclusion in this directory is not an endorsement.